在全身性硬化症中通过向早期生长反应1表达,通过Iguratimod减弱纤维化
Lichong Shen1, Hanlin Yin1, Li Sun2
1Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200001, China.
Arthritis research & therapy
|August 18, 2023
概括
伊古拉提莫德通过向纤维细胞的早期生长反应1 (EGR1) 表达,有效地减少系统性硬化 (SSc) 中的纤维化. 这种药物在改善皮肤纤维化和减少SSc模型中的原蛋白含量方面表现有前途.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 早期生长反应1 (EGR1) 是系统性硬化症 (SSc) 发展的关键因素.
- 伊古拉提莫德是一种抗风湿药物,抑制了B细胞中的EGR1表达.
研究的目的:
- 为了研究iguratimod在全身性硬化症中的抗纤维效应.
- 探索EGR1抑制在iguratimod治疗作用中的作用.
主要方法:
- 使用免疫光学,实时PCR和西布洛特的EGR1表达分析.
- 在人体皮肤纤维细胞以EGR1调节的体外研究.
- 在体内研究中,使用白素诱导和TSK-1小鼠模型的SSc.
- RNA测序以识别纤维细胞和异种移植中的iguuratimod调节基因.
主要成果:
- 在SSc患者的非免疫细胞中,EGR1的表达很高.
- 伊古拉提莫德降低了纤维细胞中的EGR1表达和TGFβ调节基因.
- 伊古拉提莫德减弱了纤维细胞激活和细胞外基质的产生,这种效应因EGR1过度表达而逆转.
- 在小鼠模型中,Iguratimod治疗降低了皮肤纤维化和SSc患者异端移植中的原蛋白含量.
结论:
- 在SSc模型中,Iguratimod在SSc模型中显示出显著的抗纤维效应.
- 向EGR1表达是一种可能的机制,可能是iguratimod在SSc中的抗纤维性活性的基础.
相关概念视频
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
150
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
150
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173


